title: Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin.
abstract: A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5-10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58% vs 68%), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease.
authors.affiliation: Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nakai
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: S
authors.initials: S
authors.lastname: Mineishi
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Ohnishi
authors.forename: H
authors.initials: H
authors.lastname: Niiya
authors.forename: A
authors.initials: A
authors.lastname: Chizuka
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Matsubara
authors.forename: M
authors.initials: M
authors.lastname: Kami
authors.forename: A
authors.initials: A
authors.lastname: Makimoto
authors.forename: R
authors.initials: R
authors.lastname: Tanosaki
authors.forename: H
authors.initials: H
authors.lastname: Kunitoh
authors.forename: K
authors.initials: K
authors.lastname: Tobinai
authors.forename: Y
authors.initials: Y
authors.lastname: Takaue
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000097:blood; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D002066:Busulfan / Q000008:administration & dosage; D017338:Cladribine / Q000008:administration & dosage; D015331:Cohort Studies; D003587:Cytomegalovirus / Q000254:growth & development / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D007107:Immune System / Q000254:growth & development / Q000821:virology*; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000706:statistics & numerical data; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology / Q000209:etiology; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000956:Antigens, Viral; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D017338:Cladribine; D002066:Busulfan